GPT and type 2 diabetes mellitus: Between study heterogeneity was found for ALT (I2 = 92.3%) The heterogeneity diminished when subgroup analysis was conducted on trial duration ≤ 8 weeks (I2 = 0.0%, P = 0.433), intervention dose >1 g/d (I2 = 48.4%, P = 0.121), overweight (25–29.9 kg/m2) (I2 = 30.2%, P = 0.220), obese (>30 kg/m2) (I2 = 63.2%, P = 0.066), type 2 diabetes (I2 = 42.8%, P = 0.155), and other health status (I2 = 69.8%, P = 0.069) (Table 3).